Recently, I participated in the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) meeting as PhRMA’s non-voting liaison. This was my first time in this new role and a great honor. As someone who has spent years caring for patients suffering from illnesses that are now preventable through vaccines, this experience was not one that I took lightly. The ACIP meetings bring together medical and public health experts to discuss critical issues related to public health and vaccination. The recommendations from ACIP stand as public health guidance on the use of vaccines to control disease in the United States.
Here are some key takeaways from the event:
Understanding pneumococcal disease
Pneumococcal disease is caused by the bacteria Streptococcus pneumoniae. It can lead to various infections ranging from mild to severe and life-threatening conditions like pneumonia, meningitis and bacteremia. Vaccination is a powerful tool in preventing these infections, and the committee's support for increasing access to pneumococcal vaccines for individuals age 50 and older is an important step to improving public health.
Vaccine schedule for meningococcal disease
Another critical topic was the immunization schedule for meningococcal disease. This disease is particularly dangerous as it leads to life-threatening meningitis — inflammation of the protective membranes covering the brain and spinal cord. Vaccines are available today which prevent most forms of this invasive disease. Caused by Neisseria meningitidis, meningococcal disease can progress rapidly, often resulting in severe complications or death within hours of symptom onset. The committee's discussion emphasized the importance of unifying the recommended vaccination schedule to protect vulnerable populations, including adolescents and young adults, who are at higher risk.
Continuing the fight against COVID-19
I continue to be amazed by how COVID-19 vaccines and therapeutics changed the way we think about the pandemic, preparedness and the way it impacts the health care system. I’m so grateful for these advances and was recently able to get my COVID-19 booster along with the flu shot. To maintain the best levels of protection, the ACIP endorsed allowing individuals 65 and up and the immunocompromised to receive a second updated vaccine six months after the first dose. A reminder that the CDC recommends all Americans ages 6 months and older get a shot of the updated 2024-2025 COVID-19 vaccine.
RSV vaccination strategies
Respiratory Syncytial Virus (RSV) was also on the ACIP meeting agenda. RSV is a common respiratory virus that causes infections of the lungs and respiratory tract. As an emergency physician, some of the scariest moments I’ve had were caring for infants experiencing respiratory distress caused by RSV –– including my own son. The committee's focus on RSV vaccination strategies highlighted the need to protect susceptible individuals and improve public health. While the U.S. Food and Drug Administration has approved vaccines for use in pregnant women and older adults and ACIP currently recommends RSV vaccinations for adults aged 60 and older, the committee is still reviewing recommendations for expanding access to adults under the age of 60 who are at an increased risk of lower respiratory tract disease. I am hopeful that vaccines can be a tool to lower the burden of disease on individuals and the health care system as a whole, since we tend to see large surges in winter months.
Increasing HPV vaccination rates
Human Papillomavirus (HPV) is another area where vaccination plays a crucial role. HPV is a group of related viruses, some of which are associated with various cancers, including cervical, anal and throat cancers. The ACIP's commitment to discussing and improving HPV vaccination rates underscores the importance of preventing these cancers through early vaccination. I was excited to recently get both of my kids vaccinated against HPV.
As I sat in the ACIP virtual meeting room, surrounded by experts, I couldn't help but reflect on my experiences in the emergency department, as a parent and emergency physician working to protect the innovative system that is bringing these incredible tools to patients. I have treated countless patients suffering from diseases that are now preventable thanks to vaccines. And I look forward to declining rates of diseases with vaccines that are now coming down the pike. The ability to prevent such suffering through immunization is a powerful reminder of the importance of our work.
The discussions at the ACIP meeting were not just academic exercises; they were science-based conversations about saving lives and improving the quality of life for millions of people. It reinforced my belief in the power of vaccination to prevent disease and protect public health. I am grateful for the opportunity to contribute to these important discussions and look forward to continuing this vital work.
Mike Ybarra
Michael Ybarra, M.D., is an emergency physician and Chief Medical Officer at PhRMA. He also serves as Senior Vice President in Advocacy and Strategic Alliances. In these roles, he leads PhRMA’s stakeholder engagement and strategic partnerships on federal and international health policy issues. He is PhRMA’s liaison representative to the Advisory Committee on Immunization Practices and is the co-convener of PhRMA’s R&D Leadership Forum. Dr. Ybarra continues to see patients clinically in the emergency department at MedStar Georgetown University Hospital.
Follow Mike on LinkedIn and X.
Mike Ybarra
Why smart vaccine policy matters
New study: HPV vaccination helps prevent cervical cancer deaths
New research reinforces the importance of hepatitis B vaccination at birth
World Immunization Week: Putting preventable diseases in the past
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
New study: Measles setbacks harm health and America’s economy
Why the hepatitis B vaccine matters
Vaccines and autism: Decades of scientific evidence find no link
Why the vaccine injury program matters
Recognizing the importance of vaccination for American health and security
Answering common questions on mRNA technology
What to know about vaccine ingredients: Aluminum and thimerosal
World Immunization Week: Highlighting the importance of vaccines for public health
What you need to know: Measles and the MMR vaccine
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Leveraging the power of vaccines to prevent antimicrobial resistance
The Patient Perspective: Vaccines
How to protect your children’s health this school year
New Report: Vaccines continue to drive improved health outcomes
Showcasing the promise of biopharma at ASCO 2024
World Vaccine Congress: Building on vaccine success
WHO Pandemic Agreement offers opportunities and risks for American innovators
New Report: 1,600 cancer treatments and vaccines in clinical development
What you should know about protecting your health this fall
A conversation with Dr. Mike Ybarra on the current state of COVID-19
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
What we’ve learned from three years of fighting COVID-19
Word of the Month: What is TRIPS?
What you should know about RSV
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Global COVID-19 vaccination matters now and for the future
Understanding breakthrough COVID-19 infections
The important role of antivirals in the fight against COVID-19
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
Americans 12 years of age and older are eligible for COVID-19 vaccines
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Patient safety is at the heart of COVID-19 vaccine R&D
Data shows that Americans are relying on vaccines to get us through the pandemic
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
Growing trend: Increased vaccine confidence
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Understanding the emergency use authorization process for COVID-19 vaccines
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Supporting access to vaccines for Part D beneficiaries
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Why vaccines work in the fight against measles and other infectious diseases
Medicare Monday: Helping beneficiaries access vaccines
New report and event examine the new era of vaccines
Medicare Monday: Strengthening access to vaccines for seniors
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
Vaccines
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting